| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Cyclooxygenase (COX); drug metabolite; amino acids and derivatives. Acexamic acid inhibits COX enzymes, reducing prostaglandin synthesis and exerting anti-inflammatory effects. As the ligand component of zinc acexamate, it contributes to the gastroprotective activity of the zinc complex. The compound is also classified as a drug metabolite derived from HMBA.
|
|---|---|
| ln Vitro |
Acexamic acid demonstrates anti-inflammatory activity in vitro through inhibition of COX enzymes. As a zinc chelator, it contributes to the gastroprotective effects of zinc acexamate by modulating mucosal protection and reducing gastric acid secretion. The compound exhibits less activity compared to its parent compound HMBA and does not induce cell differentiation, making it suitable for specific research applications.
|
| ln Vivo |
In vivo, Acexamic acid is used as an anti-inflammatory agent and as the organic ligand in zinc acexamate for the treatment of gastric ulcers and small bowel inflammation. Zinc acexamate demonstrates both antisecretory and gastroprotective properties. The compound is often administered orally as part of zinc acexamate formulations for the inhibition of gastrointestinal diseases.
|
| Enzyme Assay |
In vitro COX inhibition assays for Acexamic acid involve measuring COX-1 and COX-2 activity in the presence of varying concentrations of the compound. The enzymes are incubated with arachidonic acid substrate, and prostaglandin production is measured using ELISA or other detection methods. IC50 values are determined from dose-response curves. Zinc chelation assays can also be performed to characterize the compound's metal-binding properties.
|
| Cell Assay |
Cellular assays for Acexamic acid involve culturing gastric epithelial cells or intestinal cells. Cells are treated with Acexamic acid or zinc acexamate at varying concentrations (typically 10-1000 µM) for 24-48 hours. Cytokine production, prostaglandin synthesis, and markers of mucosal protection are measured. Cell viability is assessed using standard assays such as MTT. The compound's effects on inflammatory signaling pathways can be assessed using Western blotting.
|
| Animal Protocol |
In vivo animal studies for Acexamic acid are typically conducted in rodent models of gastric ulceration or intestinal inflammation. The compound is administered orally as zinc acexamate. Ulcer indices, gastric acid secretion, and mucosal protection are assessed. Inflammatory markers and tissue damage are evaluated histologically. Dosing regimens vary, with typical doses ranging from 10-100 mg/kg/day depending on the study objectives.
|
| ADME/Pharmacokinetics |
Acexamic acid has a molecular weight of 173.21 g/mol and a molecular formula of C8H15NO3. It has a purity of ≥99% and is soluble in DMSO and water. The compound should be stored at -20°C for up to 3 years as a powder or at -80°C for up to 1 year in solvent. Detailed pharmacokinetic parameters are not extensively documented.
|
| Toxicity/Toxicokinetics |
Acexamic acid is generally considered safe at therapeutic doses. As the ligand component of zinc acexamate, it is well-tolerated when administered orally. Comprehensive toxicological data are limited. The compound is intended for research use and is not approved for human therapeutic applications in many jurisdictions. Standard laboratory safety precautions should be taken when handling the compound.
|
| Additional Infomation |
Acexamic is a medium-chain fatty acid.
Acexamic acid (6-acetamidohexanoic acid) is an amino acid derivative and COX inhibitor used as an anti-inflammatory agent and as the organic ligand in zinc acexamate for gastric ulcer treatment. It is a metabolite derived from hexamethylene bisacetamide. The compound is not approved for clinical use in many jurisdictions and is available for research purposes only. |
| Molecular Formula |
C8H15NO3
|
|---|---|
| Molecular Weight |
173.21
|
| Exact Mass |
173.105
|
| CAS # |
57-08-9
|
| Related CAS # |
36392-66-2 (calcium salt);7234-48-2 (mono-hydrochloride salt)
|
| PubChem CID |
2005
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
404.5±28.0 °C at 760 mmHg
|
| Melting Point |
102-104 °C(lit.)
|
| Flash Point |
198.4±24.0 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.462
|
| LogP |
-0.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
12
|
| Complexity |
156
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WDSCBUNMANHPFH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H15NO3/c1-7(10)9-6-4-2-3-5-8(11)12/h2-6H2,1H3,(H,9,10)(H,11,12)
|
| Chemical Name |
6-Acetamidohexanoic acid
|
| Synonyms |
Acexamic acid NSC-12945 NSC12945NSC 12945 Plastenan
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~577.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.7733 mL | 28.8667 mL | 57.7334 mL | |
| 5 mM | 1.1547 mL | 5.7733 mL | 11.5467 mL | |
| 10 mM | 0.5773 mL | 2.8867 mL | 5.7733 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05347654 | Recruiting | Other: Local treatment with silver sulphadiazine only |
Burns Degree Second | Hospices Civils de Lyon | January 20, 2023 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
